Myocet Plus Endoxan for Older Patients With Breast Cancer

Summary

This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of older patients (≥ 70 years old) with metastatic breast cancer. The efficacy of the combination will be correlated with the functional status of patients according to the comprehensive geriatric assessment

Timeline

Start

2009-09

Primary completion

2015-05

Completion

2015-05

Outcome

Outcome not reported

Stopped (Enrollment): “Due to poor accrual”

Drugs

Indications